300759 Pharmaron Beijing
- 19.25
- -1.39-6.73%
Pharmaron Beijing News
Pharmaron (03759) received a total of 26.38 million shares released from pledge by its actual controller on May 31.
Pharmaron (03759) announced recently that it has received letters from the company's actual controllers, Lou Xiaoqiang and Zhengbei, notifying of...
Pharmaron (300759.SZ) has repurchased a total of 6.8387 million shares at a cost of 150 million yuan.
Pharmaron (300759.SZ) announced that as of May 31, 2024, it repurchased 6.8387 million shares in the centralized bidding trading method, accounting for 0.38% of the company's current total share capital, with a total transaction amount of 150 million yuan (excluding transaction fees).
Changes in Hong Kong stocks | CRO concept stocks picked up in early trading, and many companies began to adjust their business in the US. Institutions say industry demand is expected to recover in the second half of the year
CRO concept stocks picked up in early trading. As of press release, Viva Biotech (01873) rose 3.13% to HK$0.66; Kanglong Chemical (03759) rose 2.82% to HK$9.86; Pharmaceutical Biotech (02269) rose 2.68% to HK$11.5; and Pharmaceuticals (02359) rose 2.31% to HK$35.45.
Kanglong Chemical (03759.HK): Yongxin Kangjun Fund has completed the industrial and commercial registration procedures
Gelonghui, May 24, 丨 Kanglong Chemical (03759.HK) announced that on December 22, 2023, Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. (hereinafter referred to as the “Company”) held the 5th meeting of the 3rd board of directors and the 5th meeting of the 3rd board of supervisors to review and pass the “Proposal on Participation in Private Equity Investment Funds and Related Transactions”, agreeing that the company, as a limited partner, will use its own capital to commit RMB 280 million, and the related party Kangjun Investment Management (Beijing) Co., Ltd. as a general partner and associated party, Beijing Xinyuan Kang Management consulting partnership (yes
Changes in Hong Kong stocks | CRO concept stocks declined in the afternoon, minutes of the Federal Reserve meeting, Phased adjustment of Eagle Pharmaceutical Investment and financing
The decline in CRO concept stocks widened in the afternoon. As of press release, Kanglong Chemical (03759) fell 3.99% to $10.58; Tiger Pharmaceuticals (03347) fell 3.93% to HK$34.25; and Kingsley Biotech (01548) fell 3.86% to $10.96.
Kanglong Chemical (03759.HK) spent 16.616 million yuan to buy back 762,200 A shares on May 21
Kanglong Chemical (03759.HK) announced that it spent 16.616 million yuan to buy back 762,200 A shares on May 21.
Trending Industry Today: GENSCRIPT BIO Leads Losses In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
May 21st - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(LIST1261.HK)$ is trending lower today with 9 constituents down and GENSCRIPT BIO leading Losses.$GENS
Changes in Hong Kong stocks | CRO concept stocks collectively declined, and many Federal Reserve officials Fangying Pharmaceutical Outsourcing began to adjust business in the US
The Zhitong Finance App learned that CRO concept stocks were collectively lower. As of press release, Kingsley Biotech (01548) fell 4.77% to 11.58 yuan; Gloria Ying (06821) fell 4.27% to 61.65 yuan; Kanglong Chemical (03759) fell 3.65% to 11.08 yuan; Pharmaceuticals (02359) fell 3.46% to HK$39.1; Tiger Pharmaceuticals (03347) fell 3.35% to HK$34.6. According to the news, a number of Federal Reserve officials said in their Monday speech that more progress is needed on the inflation issue before interest rate cuts can be obtained
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Kanglong Chemical (03759) plans to sell its shares in Proteologix Investments and is expected to receive an initial payment of approximately US$86.821 million
Kanglong Chemical (03759) issued an announcement regarding the sale of the Group's interest in PROTEOLOGIX, INC.
Kanglong Chemical (03759) spent 128 million yuan to buy back 5.826,500 A shares on May 17
Kanglong Chemical (03759) announced that on May 17, 2024, the company spent 128 million yuan to buy back...
Kanglong Chemical (03759) will distribute the 2023 final dividend of 2 yuan for every 10 shares on July 26
Kanglong Chemical (03759) announced that the company will distribute the end of 2023 on July 26, 2024...
NOTICE OF THE ANNUAL GENERAL MEETING OF 2023
Trending Industry Today: WUXI APPTEC Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
May 14th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending higher today with 9 constituents up and WUXI APPTEC leading Gains.$WUXI APPTE
Changes in Hong Kong stocks | CRO concept stocks had the highest increase in the new US bill introducing an 8-year exemption period, and negative risks of short-term overseas policies were implemented
The Zhitong Finance App learned that CRO concept stocks had the highest gains. As of press release, Yao Ming Kangde (02359) rose 6.28% to HK$42.3; Pharmaceutical Biotech (02269) rose 5.52% to HK$14.92; Kingsley Biotech (01548) rose 4.86% to HK$12.52; Kanglong Chemical (03759) rose 4.93% to HK$11.5. According to the news, last Friday local time, Brad R. Wenstrup, a Republican member of the US House of Representatives, initiated a new version of the Biosafety Act (H.R. 8333).
Changes in Hong Kong stocks | Pharmaceutical Biotech (02269) rose more than 5%, leading the CRO concept financing environment, which is expected to improve the market and continue to monitor the progress of the Aesthetic Biology Act
CRO concept stocks generally rose in early trading. As of press release, Pharmaceuticals (02269) rose 4.67% to HK$14.78; Kanglong Chemical (03759) rose 4.15% to HK$10.28; Pharmaceuticals (02359) rose 3.02% to HK$37.5; and Tiger Pharmaceuticals (03347) rose 2.58% to HK$35.8.
Kanglong Chemical (300759.SZ): Initial repurchase of 250,000 shares involving 4.9874 million yuan
Gelonghui, May 8, 丨 Kanglong Huacheng (300759.SZ) announced that on May 8, 2024, the company used its own funds to repurchase shares through centralized bidding transactions for the first time through a special stock repurchase securities account. The number of shares repurchased was 250,000 shares, accounting for 0.01% of the company's current total share capital (1,787,394,297 shares). The highest transaction price of the repurchase was 19.99 yuan/share, and the total transaction amount was 49,874.33 million yuan (excluding transaction fees).
Kanglong Chemical (03759.HK) spent 4.987 million yuan to buy back 250,000 A shares on May 8
Gelonghui, May 8, 丨 Kanglong Chemical (03759.HK) announced that it spent 4.987 million yuan to buy back 250,000 A-shares on May 8, 2024.
Kanglong Chemical (03759) spent 4.9874 million yuan to buy back 250,000 A shares on May 8
According to the Zhitong Finance App, Kanglong Chemical (03759) announced that on May 8, 2024, the company spent 4.9874 million yuan to repurchase 250,000 A shares, with a repurchase price of HK$19.92-19.99 per share.
Kanglong Chemical announced that it had not repurchased shares as of the end of April
Kanglong Chemical (03759) announced that during the period from April 26, 2024 to April 30, 2024 (a total of three trading days), the company did not repurchase shares. The company will then implement a share repurchase plan within the repurchase period according to market conditions, and promptly fulfill its information disclosure obligations in accordance with relevant laws and regulations. Investors are kindly requested to pay attention to investment risks.
Analysis
Price Target
No Data
